Impact of Pre‐Heart Transplant Levosimendan Administration on Post‐Transplant Vasoplegia and Primary Graft Dysfunction
Clinical Transplantation · 2025
DOI: 10.1111/ctr.70327 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Clinical Transplantation, 2025. Verfasst von Joan Guzman-Bofarull und 9 weiteren Autor:innen. Beteiligte Einrichtung: Hospital Clínic de Barcelona, IDIBAPS, Barcelona, Spain. Hauptthemen laut MEDLINE: Simendan, Vasoplegia, Heart Transplantation, Primary Graft Dysfunction. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Centro de Investigación Biomédica en Red Enfermedades Cardiovasculares, Fundación Alfonso Martín Escudero, Sociedad Española de Cardiología.
Abstract (Originalsprache)
Introduction
Levosimendan, a calcium‐sensitizing inotropic agent, is used in patients with advanced heart failure (HF) awaiting heart transplantation (HT). Its prolonged effects, due to an active metabolite, may influence post‐transplant vasodilation, particularly when administered shortly before HT. However, its impact on post‐HT complications such as vasoplegia and primary graft dysfunction (PGD) remains unclear. This study aimed to evaluate whether preoperative levosimendan affects these outcomes.
Methods
This retrospective, multicenter observational study included adult HT recipients from 2010 to 2022 across three Spanish centers. Patients were grouped based on whether they received levosimendan within 1 month prior to HT. Main outcomes were post‐HT vasoplegia (defined as cardiac index ≥2.5 L/min/m 2 , systemic vascular resistance 20 or norepinephrine administration >0.1 µg/kg/min at 24 h post‐HT) and severe PGD, as defined by the 2014 ISHLT criteria. Secondary outcomes included all‐cause mortality. Subgroup analyses were performed for patients receiving levosimendan within 1 week of HT and by sex. Statistical analyses included propensity score (PS) matching, Kaplan–Meier curves, and multivariate Cox regression models.
Results
Among 598 HT recipients, 94 (15.7%) received levosimendan preoperatively. After PS adjustment, no significant differences were found in the incidence of vasoplegia (40.0% vs. 39.2%, OR 0.99, p = 0.98) or severe PGD (10.6% vs. 10.3%, OR 1.25, p = 0.63) between groups. Post‐HT mortality was also not different (HR 0.78, p = 0.37). Vasoplegia did not affect mortality, while severe PGD was linked to higher mortality. Subgroup and sex‐based analyses revealed no significant outcome differences.
Conclusions
Pre‐HT levosimendan use was not associated with increased early post‐transplant complications and appears to be a safe strategy. Summary This study evaluated whether giving levosimendan before HT affects early post‐transplant complications. Among 598 patients, 94 received levosimendan within a month before surgery. Results showed no significant differences in rates of vasoplegia, severe primary graft dysfunction, or mortality. Levosimendan use appears safe in the immediate pre‐transplant setting.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hospital Clínic de Barcelona, IDIBAPS, Barcelona, Spain.
- Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona, Barcelona, Spain.
- Hospital Puerta de Hierro, Madrid, Spain.
- Complejo Hospitalario Universitario De A Coruña (CHUAC), Instituto de Investigación Biomédica De A Coruña (INIBIC), A Coruña, Spain.
- Centro De Investigación Biomédica En Red de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain.
- Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain.
ORCID-Profile: Joan Guzman-Bofarull, Alba Martín-Centellas, David Couto-Mallon, Roger Borràs, Andrea Arenas-Loriente, Mercedes Rivas-Lasarte, Javier Segovia-Cubero, María G Crespo-Leiro, Ana García-Álvarez, Marta Farrero
Förderung
- Centro de Investigación Biomédica en Red Enfermedades Cardiovasculares
- Fundación Alfonso Martín Escudero
- Sociedad Española de Cardiología
Zitieren
APA
Guzman-Bofarull, J., Martín-Centellas, A., Couto-Mallon, D., Borràs, R., Arenas-Loriente, A., Rivas-Lasarte, M., Segovia-Cubero, J., Crespo-Leiro, M. G., García-Álvarez, A., & Farrero, M. (2025). Impact of Pre‐Heart Transplant Levosimendan Administration on Post‐Transplant Vasoplegia and Primary Graft Dysfunction. Clinical Transplantation. https://doi.org/10.1111/ctr.70327
Vancouver
Guzman-Bofarull J, Martín-Centellas A, Couto-Mallon D, Borràs R, Arenas-Loriente A, Rivas-Lasarte M, et al. Impact of Pre‐Heart Transplant Levosimendan Administration on Post‐Transplant Vasoplegia and Primary Graft Dysfunction. Clinical Transplantation. 2025. doi:10.1111/ctr.70327
BibTeX
@article{GuzmanBofarull2025,
author = {Guzman-Bofarull, Joan and Martín-Centellas, Alba and Couto-Mallon, David and Borràs, Roger and Arenas-Loriente, Andrea and Rivas-Lasarte, Mercedes and Segovia-Cubero, Javier and Crespo-Leiro, María G and García-Álvarez, Ana and Farrero, Marta},
title = {Impact of Pre‐Heart Transplant Levosimendan Administration on Post‐Transplant Vasoplegia and Primary Graft Dysfunction},
journal = {Clinical Transplantation},
year = {2025},
doi = {10.1111/ctr.70327}
}
EUVIMED